Introduction and marketing status of Dinutuximab

Dinutuximab (Dinutuximab) is a chimeric monoclonal antibody drug targeting the GD2 antigen. It is mainly used to treat high-risk neuroblastoma (Neuroblastoma). The disease usually occurs in children, especially those under five years old. DinutuximabBy recognizing the GD2 antigen on the surface of tumor cells, it activates natural killer cells and macrophages in the immune system, thus Triggers antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), effectively killing neuroblastoma cells.

Dinutuximab was first developed by United Therapeutics in the United States, and was approved by the FDA in 2015 under the trade name Unituxin. Subsequently, the drug was also approved in many countries and regions such as Europe, Japan, and Australia, and became an important maintenance therapy for the treatment of high-risk neuroblastoma, especially to reduce the risk of disease recurrence after patients complete multimodal initial treatment (such as surgery, chemotherapy, stem cell transplantation, and radiotherapy).

In recent years, as domestic attention to the treatment of malignant tumors in children has increased, Dinutuximab has also attracted widespread attention. The drug has been officially approved for marketing in mainland China, marking that domestic children with neuroblastoma will have the opportunity to receive more advanced immunotherapy methods. This progress has important clinical significance in improving treatment effects, prolonging survival, and reducing recurrence. It is also expected to improve the treatment pattern of rare tumors in children in China.

AlthoughDinutuximab has clear efficacy, its use still requires strict control and medical monitoring. Common adverse reactions during treatment include fever, hypotension, neuropathic pain, allergic reactions, etc., so treatment must be performed in an experienced children's cancer center and combined with supportive therapy (such as analgesics and anti-allergic drugs) to manage side effects. With the advancement of marketing and the gradual implementation of medical insurance policies, it is expected that more families will be able to benefit from this new targeted therapy.

References:

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package-dinutuximab